Patents by Inventor Alexander Oksche

Alexander Oksche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE
    Publication number: 20240082149
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Application
    Filed: September 19, 2023
    Publication date: March 14, 2024
    Inventors: John Strang, Alexander Oksche, Stephen Harris, Kevin Smith, Lucie Helene Jeanne Mottier
  • Intranasal pharmaceutical dosage forms comprising naloxone
    Patent number: 11806428
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: November 7, 2023
    Assignee: HARM REDUCTION THERAPEUTICS, INC.
    Inventors: John Strang, Alexander Oksche, Stephen Harris, Kevin Smith, Lucie Helene Jeanne Mottier
  • INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE
    Publication number: 20210338574
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Application
    Filed: April 23, 2021
    Publication date: November 4, 2021
    Inventors: John Strang, Alexander Oksche, Stephen Harris, Kevin Smith, Lucie Helene Jeanne Mottier
  • Intranasal pharmaceutical dosage forms comprising naloxone
    Patent number: 11020343
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HC dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: June 1, 2021
    Assignee: Harm Reduction Therapeutics, Inc.
    Inventors: John Strang, Alexander Oksche, Stephen Harris, Kevin Smith, Lucie Helene Jeanne Mottier
  • DIHYDROETORPHINE FOR THE PROVISION OF PAIN RELIEF AND ANAESTHESIA
    Publication number: 20210085673
    Abstract: The present invention provides a method of providing pain relief in a human subject in need thereof comprising administering (R)-dihydroetorphine to said subject, wherein said (R)-dihydroetorphine is administered in a dose of at least 0.01 ?g/kg, preferably at least 0.05 ?g/kg, and the level of respiratory depression in said subject is 65 or less % relative to the baseline level pre-administration of (R)-dihydroetorphine.
    Type: Application
    Filed: September 30, 2020
    Publication date: March 25, 2021
    Applicant: EURO-CELTIQUE S.A.
    Inventors: John WATKINS, Alexander Oksche, Kevin Smith, Heikki Mansikka, Paul Bailey
  • Dihydroetorphine for the provision of pain relief and anaesthesia
    Patent number: 10898479
    Abstract: The present invention provides a method of providing pain relief in a human subject in need thereof comprising administering (R)-dihydroetorphine to said subject, wherein said (R)-dihydroetorphine is administered in a dose of at least 0.01 ?g/kg, preferably at least 0.05 ?g/kg, and the level of respiratory depression in said subject is 65 or less % relative to the baseline level pre-administration of (R)-dihydroetorphine.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: January 26, 2021
    Assignee: Euro-Celtique S.A.
    Inventors: John Watkins, Alexander Oksche, Kevin Smith, Heikki Mansikka, Paul Bailey
  • INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE
    Publication number: 20190374464
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HC dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Application
    Filed: August 23, 2019
    Publication date: December 12, 2019
    Inventors: John STRANG, Alexander OKSCHE, Stephen HARRIS, Kevin SMITH, Lucie Helene Jeanne MOTTIER
  • Buprenorphine-wafer for drug substitution therapy
    Publication number: 20190216797
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Application
    Filed: August 17, 2018
    Publication date: July 18, 2019
    Inventors: Alexander Oksche, William Heath, Timothy Holden, Derek A. Prater, Richard S. Sackler, Malcolm Walden
  • Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
    Patent number: 10071089
    Abstract: The present invention is concerned with an oral pharmaceutical dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain in patients suffering from i) pain and at least one further disease ii), wherein said at least one further disease ii) results in intestinal dysbiosis, or for use in the treatment of pain in patients suffering from i) pain and at least one further disease iii), wherein said at least one further disease iii) increases the risk for intestinal bacterial translocation and thus for peritonitis, SIRS and/or sepsis.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: September 11, 2018
    Assignee: Euro-Celtique S.A.
    Inventors: Yvonne Von Coburg, Karen Reimer, Alexander Oksche, Peter Holzer
  • BUPRENORPHINE WAFER FOR DRUG SUBSTITUTION THERAPY
    Publication number: 20180008595
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Application
    Filed: September 19, 2017
    Publication date: January 11, 2018
    Inventors: Alexander OKSCHE, William HEATH, Timothy HOLDEN, Derek A. PRATER, Richard S. SACKLER, Malcolm WALDEN
  • Buprenorphine-wafer for drug substitution therapy
    Patent number: 9861628
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: January 9, 2018
    Assignee: RHODES PHARMACEUTICALS L.P.
    Inventors: Alexander Oksche, William Heath, Timothy Holden, Derek A. Prater, Richard S. Sackler, Malcolm Walden
  • INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE
    Publication number: 20170304192
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Application
    Filed: May 9, 2017
    Publication date: October 26, 2017
    Inventors: John STRANG, Alexander OKSCHE, Stephen HARRIS, Kevin SMITH, Lucie Helene Jeanne MOTTIER
  • Opioid composition for treating skin lesions
    Patent number: 9782359
    Abstract: The present invention relates to a composition, comprising (i) a matrix made of polymeric nanofibers, and (ii) an opioid agonist within the matrix.
    Type: Grant
    Filed: May 5, 2009
    Date of Patent: October 10, 2017
    Assignee: EURO-CELTIQUE S.A.
    Inventors: Alexander Oksche, Kevin J. Smith, Derek Prater, Malcolm Walden, Will Heath, Bernard Kennedy, Vanessa Addison
  • Buprenorphine-wafer for drug substitution therapy
    Patent number: 9763931
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: September 19, 2017
    Assignee: PURDUE PHARMA L.P.
    Inventors: Alexander Oksche, William Heath, Timothy Holden, Derek A. Prater, Richard S. Sackler, Malcolm Walden
  • Intranasal Pharmaceutical Dosage Forms Comprising Naloxone
    Publication number: 20170231904
    Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
    Type: Application
    Filed: January 27, 2017
    Publication date: August 17, 2017
    Inventors: John STRANG, Alexander OKSCHE, Stephen HARRIS, Kevin SMITH, Lucie Helene Jeanne MOTTIER
  • Buprenorphine-Wafer for Drug Substitution Therapy
    Publication number: 20170157062
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Application
    Filed: February 24, 2017
    Publication date: June 8, 2017
    Inventors: Alexander OKSCHE, William HEATH, Timothy HOLDEN, Derek A. PRATER, Richard S. SACKLER, Malcolm WALDEN
  • Buprenorphine-wafer for drug substitution therapy
    Publication number: 20160235738
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Application
    Filed: April 22, 2016
    Publication date: August 18, 2016
    Inventors: Alexander OKSCHE, William HEATH, Timothy HOLDEN, Derek A. PRATER, Richard S. SACKLER, Malcolm WALDEN
  • BUPRENORPHINE WAFER FOR DRUG SUBSTITUTION THERAPY
    Publication number: 20160235739
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Application
    Filed: April 22, 2016
    Publication date: August 18, 2016
    Inventors: Alexander OKSCHE, William HEATH, Timothy HOLDEN, Derek A. PRATER, Richard S. SACKLER, Malcolm WALDEN
  • A COMBINATION OF OXYCODONE AND NALOXONE FOR USE IN TREATING PAIN IN PATIENTS SUFFERING FROM PAIN AND A DISEASE RESULTING IN INTESTINAL DYSBIOSIS AND/OR INCREASING THE RISK FOR INTESTINAL BACTERIAL TRANSLOCATION
    Publication number: 20160184293
    Abstract: The present invention is concerned with an oral pharmaceutical dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain in patients suffering from i) pain and at least one further disease ii), wherein said at least one further disease ii) results in intestinal dysbiosis, or for use in the treatment of pain in patients suffering from i) pain and at least one further disease iii), wherein said at least one further disease iii) increases the risk for intestinal bacterial translocation and thus for peritonitis, SIRS and/or sepsis.
    Type: Application
    Filed: July 23, 2014
    Publication date: June 30, 2016
    Inventors: Yvonne VON COBURG, Karen REIMER, Alexander OKSCHE, Peter HOLZER
  • Buprenorphine-wafer for drug substitution therapy
    Patent number: 9370512
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: June 21, 2016
    Assignee: PURDUE PHARMA L.P.
    Inventors: Alexander Oksche, William Heath, Timothy Holden, Derek A. Prater, Richard S. Sackler, Malcolm Walden